DCDC1 Inhibitors
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol can inhibit the PI3K/Akt pathway, which is involved in cell survival and proliferation. By inhibiting this pathway, resveratrol can lead to reduced activity of DCDC1, as PI3K/Akt is known to regulate a multitude of cellular functions including those related to the processes in which DCDC1 is involved. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of PI3K. Inhibition of PI3K leads to a decrease in Akt phosphorylation, and since DCDC1 function is related to pathways regulated by Akt, its activity can be indirectly decreased as a result of LY294002 action. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another potent PI3K inhibitor that prevents the phosphorylation and activation of Akt. By disrupting the PI3K/Akt signaling pathway, wortmannin can indirectly decrease the functional activity of DCDC1. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a downstream target of the PI3K/Akt pathway. By inhibiting mTOR activity, rapamycin can lead to altered protein synthesis and cellular processes where DCDC1 is implicated, thus indirectly inhibiting its function. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine specifically inhibits Akt phosphorylation and activation without affecting PI3K, leading to a decrease in cellular processes regulated by Akt, including those associated with DCDC1 function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which functions upstream of ERK in the MAPK pathway. Since DCDC1 may be influenced by the MAPK pathway, inhibiting MEK with PD98059 can indirectly reduce DCDC1 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor. By preventing JNK signaling, which may regulate transcription factors or other molecules that interact with DCDC1, the functional activity of DCDC1 can be indirectly decreased. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK. Inhibition of p38 MAPK can affect various signaling pathways and biological processes including those involving DCDC1, thus potentially decreasing its functional activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, leading to reduced ERK phosphorylation in the MAPK pathway. This could decrease DCDC1 activity by affecting cellular functions regulated by the MAPK pathway. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin has been shown to inhibit the NF-κB pathway. Since DCDC1 might be involved in processes regulated by NF-κB, curcumin can lead to a reduction in DCDC1 activity. | ||||||